New Delhi, Jun 12 (PTI) Dr Reddy's Laboratories Ltd on Wednesday said it has signed a licensing pact with US-based Ingenus Pharmaceuticals, LLC, to commercialise Cyclophosphamide injection used in treatment of cancer.

The company's wholly-owned subsidiary Dr Reddy's Laboratories Inc and Ingenus Pharmaceuticals, LLC have entered into license agreement, Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.

Also Read | Andhra Pradesh Cabinet Ministers List 2024: How Many Ministers Are in Andhra Pradesh? Who Is AP Deputy CM? Know Everything Here.

Subsequently, Dr Reddy's Laboratories Inc (Dr Reddy's USA) has licensed from Ingenus, the exclusive rights to commercialise Cyclophosphamide injection of strengths 500 mg/2.5mL; 1g/5mL; 2g/10mL in the US, it added.

Under the in-licensing pact, Dr Reddy's USA will commercialise the Cyclophosphamide injection for the US market and will pay Ingenus 50 per cent of the calculated profit share and no other consideration is payable, the filing said.

Also Read | List of Prime Ministers of India: From Jawaharlal Nehru To Narendra Modi, Know Brief History of All Leaders Who Held PM Post.

The sales of the said Ingenus product as per the IQVIA for the past 12 months ended March 2024 was USD 51.8 million, it added.

The parties will enter into a commercial supply agreement pursuant to which Ingenus will supply the product to Dr Reddy's USA, the company said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)